OrbiMed Advisors Reduces Stake in Passage Bio Amid Prolonged Stock Decline OrbiMed Advisors, a key investor in Passage Bio, has sold over 149,000 shares as the biotech’s stock continues to struggle, down more than 73% year-over-year. Despite the sell-off, OrbiMed retains a significant holding. Passage Bio is implementing cost-cutting measures and considering a reverse stock split to regain Nasdaq compliance.12